Evidence map›Paper›PMID 42397568›Full record

ArticleAnnals of hematology2026

Real-world treatment patterns and outcomes in chronic lymphocytic leukemia: a multicenter retrospective study in Greece.

Epameinondas Koumpis, Eva Minga, Persefoni Talimtzi, Maria Angelopoulou, Sofia Chatzileontiadou, Maria Dimou, Sotiria Besikli-Dimou, Maria Efstathopoulou, Dimitris Gogos, Evdoxia Hatjiharissi and 18 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Epameinondas KoumpisDepartment of Haematology, Faculty of Medicine, University of Ioannina, Greece, Ioannina, Greece.
Eva MingaInstitute of Applied Biosciences, Center for Research and Technology, Thessaloniki, Greece.
Persefoni TalimtziInstitute of Applied Biosciences, Center for Research and Technology, Thessaloniki, Greece.
Maria AngelopoulouHaematology, University of Athens, Laikon General Hospital, Athens, Greece.
Sofia Chatzileontiadou1st Dept of Internal Medicine, Hematology Unit, AUTH, AHEPA Hospital, Thessaloniki, Greece.
Maria DimouHaematology, University of Athens, Laikon General Hospital, Athens, Greece.
Sotiria Besikli-DimouHematology Department and HCT Unit G. Papanicolaou Hospital Thessaloniki, Thessaloniki, Greece.
Maria EfstathopoulouDepartment of Haematology, Athens Medical Center, Athens, Greece.
Dimitris GogosHospital of Mytilene, Mytilene, Greece.
Evdoxia Hatjiharissi1st Dept of Internal Medicine, Hematology Unit, AUTH, AHEPA Hospital, Thessaloniki, Greece.
Eleftheria HatzimichaelDepartment of Haematology, Faculty of Medicine, University of Ioannina, Greece, Ioannina, Greece.
Michail IskasHematology Department and HCT Unit G. Papanicolaou Hospital Thessaloniki, Thessaloniki, Greece.
Eliana KonstantinouHaematology, University of Athens, Laikon General Hospital, Athens, Greece.
Ioannis KotsianidisDepartment of Hematology, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece.
Alexandros MachairasHaematology, University of Athens, Laikon General Hospital, Athens, Greece.
Eugenia MpalaouraInstitute of Applied Biosciences, Center for Research and Technology, Thessaloniki, Greece.
Anastasia MpantiDepartment of Hematology, Papageorgiou Hospital, Thessaloniki, Greece.
Panagiotis PanagiotidisHaematology, University of Athens, Laikon General Hospital, Athens, Greece.
Gerasimos PangalisDepartment of Haematology, Athens Medical Center, Athens, Greece.
Ioannis PapadopoulosHematology Department and HCT Unit G. Papanicolaou Hospital Thessaloniki, Thessaloniki, Greece.
Maria Papaioannou1st Dept of Internal Medicine, Hematology Unit, AUTH, AHEPA Hospital, Thessaloniki, Greece.
Marina SiakantarisHaematology, University of Athens, Laikon General Hospital, Athens, Greece.
Niki StavroyianniHematology Department and HCT Unit G. Papanicolaou Hospital Thessaloniki, Thessaloniki, Greece.
Theodoros VassilakopoulosHaematology, University of Athens, Laikon General Hospital, Athens, Greece.
George VrachioliasDepartment of Hematology, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece.
Kostas StamatopoulosInstitute of Applied Biosciences, Center for Research and Technology, Thessaloniki, Greece.
Anastasia ChatzidimitriouInstitute of Applied Biosciences, Center for Research and Technology, Thessaloniki, Greece.
Thomas ChatzikonstantinouInstitute of Applied Biosciences, Center for Research and Technology, Thessaloniki, Greece. thomas.chatzikonstantinou@certh.gr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aims to characterize treatment patterns for chronic lymphocytic leukemia (CLL) in real-world clinical practice across Greece focusing on both treatment-naïve and relapsed or refractory (R/R) disease. We evaluated therapeutic patterns and outcomes [including overall survival (OS), time to next treatment or death (TTNT-D) and overall response rate (ORR)] and documented the incidence of other malignancies of patients who initiated first-line treatment between 2010 and 2024.

methodsThis is a panhellenic multicenter retrospective study of patients diagnosed with CLL between 2010 and 2020 from 8 centers in Greece.

resultsOverall, 1318 patients were included in the study. Fludarabine, cyclophosphamide and rituximab (FCR) was the most common first-line regimen (21.6%), followed by chlorambucil plus rituximab (16.3%) and ibrutinib-based therapies (14%). In the R/R setting, ibrutinib and venetoclax-based treatments, became the predominant therapeutic choices after 2014, replacing chemoimmunotherapy. Shifts in treatment patterns before and after 2016 reflected the incorporation of targeted agents into routine clinical practice, with a marked decline in FCR use and increased adoption of targeted therapies. Median OS was 162 months from diagnosis and 105.2 months (95% CI: 90.3-116.3) from first treatment. In patients receiving ibrutinib as first-line therapy, mOS was not reached, and median TTNT-D was 67.3 months. Overall, 18 (1.4%) cases developed a second hematological malignancy and 59 (4.5%) were diagnosed with a solid tumor. The most common hematological malignancy was myelodysplastic neoplasms and the most common solid tumors included lung, skin, breast, colon and prostate cancers.

conclusionThe findings suggest a gradual shift in CLL treatment patterns in Greece, with targeted agents increasingly replacing traditional chemoimmunotherapy in recent years and showing favorable survival outcomes.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsLeukemia, Lymphocytic, Chronic, B-CellAdenineAgedAged, 80 and overBridged Bicyclo Compounds, HeterocyclicChlorambucilCyclophosphamideFemaleGreeceHumansMaleMiddle AgedPiperidinesRetrospective StudiesRituximabAdenineBridged Bicyclo Compounds, HeterocyclicChlorambucilCyclophosphamidefludarabineibrutinibPiperidinesRituximabSulfonamidesvenetoclaxVidarabineCLLGreeceTargeted agentsTreatment patterns

Identifiers

PMID42397568
PMCPMC13597568

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.